Sunitinib Improves Progression-Free Survival in Patients With Advanced Pancreatic Islet Cell Tumors

OncologyONCOLOGY Vol 23 No 8
Volume 23
Issue 8

Pfizer announced results from a randomized phase III trial of sunitinib malate (Sutent) in patients with advanced pancreatic islet cell (neuroendocrine) tumors

Pfizer announced results from a randomized phase III trial of sunitinib malate (Sutent) in patients with advanced pancreatic islet cell (neuroendocrine) tumors. Study findings demonstrated that median progression-free survival was 11.1 months in patients treated with sunitinib compared to 5.5 months in patients treated with placebo. Researchers presented these data at the 11th World Congress on Gastrointestinal Cancer in Barcelona, Spain.

The independent Data Monitoring Committee recommended halting the trial earlier this year because sunitinib showed significant benefit and the study had met its primary endpoint. Full analysis of the data is ongoing.

Related Videos
An expert from the University of California, Los Angeles suggests that the NALIRIFOX may be a beneficial treatment for patients with pancreatic ductal adenocarcinoma.
Patients with metastatic pancreatic ductal adenocarcinoma who receive NALIRIFOX tend to have more gastrointestinal toxicity while nab-paclitaxel/gemcitabine results in more cytopenias, according to an expert from University of California, Los Angeles.
An expert from the University of California, Los Angeles described the purpose and design of the phase 3 NAPOLI-3 study, assessing NALIRIFOX in metastatic pancreatic ductal adenocarcinoma.
Shubham Pant, MD, highlights the importance of tailoring treatment in patients with pancreatic cancer by exploring biomarkers.
Related Content